Eloísa Jiménez Núñez

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Andreas Weiss, Edwige Lorthiois, Louise Barys et al. · Cancer Discovery · 2022 · 134 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli et al. · Nature Cancer · 2024 · 132 citations · Full text

Medicine, Cancer Biology, Oncology +15

Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers

Stéphane Ferretti, Jacques Hamon, Ruben de Kanter et al. · Nature · 2024 · 113 citations · Full text

Life Sciences, Oncology, Pharmacology +17

Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders

Susanne Roehrig, Jens Ackerstaff, Eloísa Jiménez Núñez et al. · Journal of Medicinal Chemistry · 2023 · 30 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Abstract LB319: IAG933, a selective and orally efficacious YAP1/WWTR1(TAZ)-panTEAD protein-protein interaction inhibitor with pre-clinical activity in monotherapy and combinations

Tobias Schmelzle, Emilie A. Chapeau, Daniel Bauer et al. · Cancer Research · 2023 · 26 citations

Medicine, Oncology, Pharmacology +15